Booming Novo Nordisk shoots for top drugmaker status

Novo Nordisk's ($NVO) CEO Lars Sorensen acknowledges there was an odd element of good fortune for the drugmaker in becoming the largest company in the Nordic region by capitalization and among the top 10 drug companies in the world. That good fortune, of course, has a flip side--an epidemic of diabetes. "What we are good at, all of a sudden becomes the biggest public health problem we have ever seen," Sorensen told the Financial Times. Report


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.